Clinical Core (Core A) is responsible for centralized functions that provide the foundation for the proposed research in this Program Project. The 4 functions of the Core are (1) to provide access to patients with ANCA disease throughout their disease course for recruitment into the proposed studies, (2) to collect, process and store biologic samples from patients at various disease stages as well as from family members and controls, (3) monitor and manage information on the long-term outcomes in patients with ANCA disease using standard definitions, and, (4) manage, integrate and process the medical and biologic information from components of all projects, which includes management of the integrated database, and statistical analyses and interpretation of results. Careful clinical characterization and long-term follow-up of patients with ANCA disease is a major effort that requires an experienced team of investigators and staff as put together by this Core. The Core provides uniform identification of remission and relapses of the disease, which facilitates the coordination of biologic sample collections during these different disease stages. Identification of patients with various levels of disease activity is also critical for determination of those eligible for proposed trials and clinical studies. The collection of biologic samples from family members of patients with ANCA disease and healthy controls can also be accomplished as required by Core A. Core A has well established methods for the collection of samples in conjunction with a database system for storage and identification of multiple samples among patients. The database allows for the unique information required for each study to be easily linked with clinical information. Core A will also provide support needed for study design and statistical analyses throughout the proposed program project, with the goal of assisting all projects in the successful and timely publication of results. This Core has been in existence under the leadership of Susan L. Hogan, PhD since the original cycle of funding for this Program Project in 1999. The overall experience and dedication of the faculty and staff of Core A will continue to bring a strong resource on which each project can depend and can, therefore, successfully launch their laudable scientific goals.
This Core provides centralized support to all 4 of the proposed research projects within the Program Project, 'ANCA Glomerulonephritis: from Molecules to Man'. The Core provides the infrastructure and centralized systems for enrolling patients into the research projects, determining the disease status of patients with ANCA-related disease, collecting biologic samples, and storage and analysis of all research data.
|Aybar, L T; McGregor, J G; Hogan, S L et al. (2015) Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies. Clin Exp Immunol 180:178-88|
|Cao, Yali; Liu, Kuo; Tian, Zhigang et al. (2015) PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis. J Rheumatol 42:292-9|
|Jennette, J Charles; Falk, Ronald J (2014) B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 36:327-38|
|Joy, Melanie S; Roberts, Brittney V; Wang, Jinzhao et al. (2014) A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther 52:303-13|
|Jennette, J Charles; Falk, Ronald J (2014) Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10:463-73|
|Xiao, Hong; Dairaghi, Daniel J; Powers, Jay P et al. (2014) C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25:225-31|
|Geetha, Duvuru; Poulton, Caroline J; Hu, Yichun et al. (2014) Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Semin Arthritis Rheum 43:778-83|
|Xiao, Hong; Ciavatta, Dominic; Aylor, David L et al. (2013) Genetically determined severity of anti-myeloperoxidase glomerulonephritis. Am J Pathol 182:1219-26|
|Jennette, J Charles (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603-6|
|Free, Meghan E; Bunch, Donna O'Dell; McGregor, Julie Anne et al. (2013) Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 65:1922-33|
Showing the most recent 10 out of 42 publications